Drugs / BTL-TML-HSV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01902303 | Jul 2013 → Sep 2014 | herpes labialis | Beech Tree Labs, Inc. | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BTL-TML-HSV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01902303 ↗ |
| Known as | BTL-TML | “Low-dose TML (BTL-TML) was evaluated for safety and efficacy against herpes labialis in two FDA-approved, randomized, double blind, placebo-controlled clinical trials.” PMID 35142535 ↗ Jan 2022 |
| Known as | TML | “Low-dose TML (BTL-TML) was evaluated for safety and efficacy against herpes labialis in two FDA-approved, randomized, double blind, placebo-controlled clinical trials.” PMID 35142535 ↗ Jan 2022 |